clinical trial · NCT05050149
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
Microcystic Lymphatic MalformationPTX-022
brief summary
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
started
Jan 13, 2022
primary completion
Nov 15, 2022
completion
Dec 15, 2022
last updated
Jan 17, 2025
official title
A Multicenter, Phase 2, Open-Label Study Evaluating The Safety And Efficacy of Sirolimus 3.9% Topical Gel (PTX-022) In The Treatment of Microcystic Lymphatic Malformations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol